Clinical Trial

AI-ECG for Predicting CMR-Defined Myocardial Injury in Acute Myocardial Infarction

Completed
View on ClinicalTrials.gov →
Summary
This retrospective, single-center external validation study evaluates whether two commercially approved artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms (AiTiA LVSD and AiTiA MI; Medical AI Co., Ltd.), applied to a single pre-percutaneous coronary intervention (PCI) 12-lead ECG, predict cardiac magnetic resonance (CMR)-defined myocardial injury in patients with acute myocardial infarction (AMI). The primary endpoint is a large infarct (late gadolinium enhancement \>17.9% of left ventricular mass); secondary endpoints are CMR left ventricular ejection fraction (LVEF) ≤40% and microvascular obstruction (MVO).
Trial Details
NCT Number NCT07751809
Lead Sponsor Yonsei University
Collaborators: Medical AI
Conditions Acute Myocardial Infarction (AMI)
Enrollment 461 participants
Start Date 2020-04-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-07